Biotech Startups

Genomate Health develops an AI-powered clinical decision support system for precision oncology that analyzes a patient's molecular profile to produce evidence-based treatment rankings for physicians. Its Genomate platform combines oncology, genomics, and computational reasoning to support personalized cancer treatment decisions.

1 investor

Genome Biologics operates a contract research service using TrueCardium, an iPSC-derived multicellular human cardiac organoid platform, to run cardiotoxicity screening, disease modeling, and drug efficacy studies. It serves pharmaceutical and biotechnology partners seeking human-relevant cardiac safety and translational data beyond conventional 2D assays and animal models.

1 investor

GenoME Diagnostics develops PCR-based diagnostic and biomarker technologies for cancer, with research programmes in ovarian and pancreatic cancer. The company builds on cancer biomarker and DNA methylation research from its academic founders.

1 investor

Omzey (formerly GenomeUp) develops JuliaOmix, a diagnostic suite designed to accelerate the diagnosis of rare diseases using omics sciences. The company serves clinicians, researchers, and patients working in rare disease diagnostics and precision medicine.

1 investor

GenomeMiner develops A.I.-driven bioinformatics and genome mining software, using DNA sequencing and proprietary data from organisms in subtropical Okinawa to identify and produce valuable natural products. Originally founded as Tupac.Bio building tools for synthetic biology companies, it aims to serve the biotech industry and eventually develop its own end-products.

1 investor

Genomic Vision is a genome analysis company whose Molecular Combing technology characterizes DNA at single-molecule resolution for quality control in bioproduction and cell and gene therapy, as well as for drug discovery research. It serves pharmaceutical, biotech, and research organizations developing gene therapies and studying DNA replication.

1 investor

GenomicMD provides clinical-grade genomic risk assessments to physicians for integrating personalized medicine into patient care, using polygenic analysis to identify disease risk and guide preventive health management. The company serves medical practices and patients seeking evidence-based genetic screening beyond traditional family history assessments.

1 investor

Genomiki develops AI/ML- and genomics-driven diagnostic, screening, and microbiome analysis tools that convert sequencing and clinical data into insights for early risk detection and personalized interventions. Its solutions are designed to integrate into clinical and wellness workflows to support medical decisions and research.

1 investor

GenomILL develops precision diagnostic technologies using genomic analysis. The company serves clinical and research customers seeking advanced molecular diagnostics.

1 investor

GenMedPro is a genetics-based medication management platform that analyzes 26 genes to identify drug-drug and gene-drug interactions across a patient's entire medication regimen. The platform serves healthcare providers and care teams to reduce prescribing errors, prevent adverse events, and optimize medication safety for complex polypharmacy cases.

1 investor

GenomSys develops modular software for storing, processing and sharing genomic data based on the ISO/IEC 23092 MPEG-G standard, serving diagnostic laboratories, hospitals, research centers and biotech companies. The company operates in computational genomics and precision medicine, with a Swiss parent company and an Italian subsidiary running its MPEG-G Competence Center in Milan.

1 investor

Genomtec develops a mobile platform for point-of-care genetic diagnostics that detects respiratory pathogens including viruses and bacteria. The company has obtained CE-IVD certification for its respiratory diagnostic panel in Europe.

1 investor

Genopore is developing a single-molecule protein identification and quantitation system that uses chemo-selective protein labeling, solid-state nanopore translocation, and AI-powered optical readout to sequence whole proteins without mass spectrometry or affinity-based methods. It targets proteomics applications such as early disease detection, biomarker discovery, and drug discovery for the life sciences research market.

1 investor

Genoskin offers MANTIS, a spatial biology platform that performs multiplex 3D imaging analysis of human skin tissue to study immune cell responses to vaccines, drugs, and cosmetics. The platform enables automated, unbiased profiling of immune cells within their tissue context using fluorescence-based imaging and proprietary computational analysis.

1 investor

Genotix Bio develops the DaVinci, a compact nanoarray analyzer that detects proteins and nucleic acids at single-molecule resolution for research applications. The instrument enables ultrasensitive biomarker detection with minimal sample volumes and fast processing times.

1 investor

Genova Diagnostics operates a clinical laboratory offering functional-medicine diagnostic tests, including gut microbiome, metabolomics, methylation, genomics, and oxidative stress panels. Its testing combines multiple technologies, including whole-genome shotgun sequencing with AI-based analysis, to help clinicians assess gut health and other physiological systems for personalized patient care.

1 investor

GenScript Biotech is a life sciences company providing reagents, custom services, instruments, and biologics development solutions to research and pharmaceutical industries globally. The company operates through subsidiaries including Bestzyme (synthetic biology), ProBio (biologics CDMO), and GenScript Life Science Group, with manufacturing and R&D centers across China, Singapore, and the United States.

1 investor

Genuity Science provides genomics research services—including study design, cohort sourcing, sample preparation, whole genome sequencing, and advanced analytics—along with disease-specific clinico-omic datasets. It serves drug discovery clients working on CNS, cardiometabolic, and inflammatory diseases to support target and biomarker programs.

1 investor

GenWorks manufactures medical devices for patient monitoring and care support across ICU, critical care, operating theater, and maternal-newborn care settings. The company produces infusion pumps, defibrillators, anesthesia machines, ventilators, and related monitoring equipment for hospitals and healthcare facilities.

1 investor

Genyro develops a DNA writing and assembly platform based on its Sidewinder technology and "page-number" barcode logic, which directs precise joining of DNA fragments to build genomes and constructs from any designed sequence. The company targets applications in biomanufacturing, programmable therapeutics, and large-scale genome and protein design for the bioeconomy.

1 investor

George Medicines develops single-pill combination therapies for cardiometabolic diseases such as hypertension and diabetes, leveraging research from The George Institute for Global Health. The company targets patients with low medication adherence and aims to reduce the burden of non-communicable diseases on patients, families, and health systems.

1 investor

Germfree provides cleanroom and biocontainment facility solutions for pharmaceutical, pharmacy, and biopharma manufacturing, leveraging over 60 years of experience and in-house fabrication technology. The company serves life science organizations developing medicines and conducting research requiring controlled laboratory environments.

1 investor

Gero is a biotech company applying AI, data science, and physics-based models of human health to discover drug targets and therapies for aging and age-related chronic diseases. It develops a therapeutic pipeline using longitudinal health data, statistical genetics, and multi-omics.

1 investor

Culturewell provides environmental microbiology testing and germ detection services to healthcare facilities for identifying contamination and preventing healthcare-associated infections. The service uses proprietary sampling methods, laboratory analysis, and AI-driven risk assessment to deliver actionable insights on cleaning compliance and outbreak prevention.

1 investor